Bahçeşehir University, Faculty of Health Sciences, Department of Nursing, İstanbul, Turkey.
Muğla Sıtkı Koçman University, Fethiye Faculty of Health Sciences, Muğla, Turkey.
Prim Care Diabetes. 2023 Aug;17(4):373-378. doi: 10.1016/j.pcd.2023.05.002. Epub 2023 May 21.
This study aimed to investigate the relationship between insulin use and stigma in Type 2 Diabetes Mellitus (T2DM).
The study was carried out in the endocrinology and metabolic disorders outpatient clinic of a state hospital between February and October 2022. The study was carried out with 154 patients, 77 of them were treated with insulin while 77 were treated with peroral antidiabetic drugs (PAD). The patient identification form and Type 2 Diabetes Stigma Assessment Scale (DSAS-2) were used for data collection. The data were analyzed by using IBM SPSS 26.0 software.
DSAS-2 total score, treated differently, blame and judgment, and self-stigma subscales were higher in insulin-treated T2DM patients compared to the patients treated with PAD. There was a positive relationship between the number of daily injections and the DSAS-2 total score (r = 0.554). Multiple linear regression showed that type of the treatment, treatment duration, number of daily injections and perceived level of health were the determinants of the DSAS-2 score.
Stigma was high in insulin-treated T2DM patients and as the number of daily injections increased, the level of the perceived stigma increased. We recommend considering the high level of perceived stigma in insulin-treated T2DM patients while preparing nursing investigations.
本研究旨在探讨 2 型糖尿病（T2DM）患者使用胰岛素与耻辱感之间的关系。
本研究于 2022 年 2 月至 10 月在一家州立医院的内分泌和代谢紊乱门诊进行。研究共纳入 154 例患者，其中 77 例接受胰岛素治疗，77 例接受口服降糖药（PAD）治疗。采用患者识别表和 2 型糖尿病耻辱感评估量表（DSAS-2）收集数据。采用 IBM SPSS 26.0 软件进行数据分析。
与接受 PAD 治疗的患者相比，接受胰岛素治疗的 T2DM 患者的 DSAS-2 总分、治疗方式不同、指责和判断以及自我耻辱感分量表得分更高。每日注射次数与 DSAS-2 总分呈正相关（r=0.554）。多元线性回归显示，治疗方式、治疗持续时间、每日注射次数和感知健康水平是 DSAS-2 评分的决定因素。
接受胰岛素治疗的 T2DM 患者的耻辱感较高，且随着每日注射次数的增加，感知耻辱感水平也随之升高。我们建议在进行护理调查时，考虑到接受胰岛素治疗的 T2DM 患者感知到的高耻辱感。
